Life Sciences Archive » September, 2011

Life Sciences - September, 2011

177 articles

• Law360 Names Most Innovative Corporate Counsel
• Alcon Can't Toss Inventor's Lens Patent Suit
• Glenmark Can't Nix Abbott's $16M Win Over Tarka Patent
• FDA Aims To Speed Reviews Of New, Low-Risk Devices
• Ex-Pfizer Employees Want Class Cert. In ERISA Suit
• Judge Clears $6M DIP Loan To Fund Graceway Ch. 11 Sale
• CVS Caremark Says Rival SXC Lured Away Workers
• DOJ Probes Cephalon Over Narcolepsy Drug Marketing
• NJ Court Shuts Down Suits Over Hormone Therapy Labeling
• AstraZeneca, Handa Settle Seroquel Patent Fight
• Leason Ellis Adds 2 IP Pros To Pharma, Biotech Group
• Merck Pays $1.6M To End Idaho AWP Fight
• Bayer Settles False Ad Suit Over Rival Acne Med
• FDA Warns Eye Doctors Again Over Laser Surgery Ads
• Contact Lens Claims Preempted By FDA Regs: 9th Circ.
• Debevoise Reps Drugmaker Galderma In Graceway Buy
• Sandoz Antitrust Claims Nixed In Bayer's Yasmin IP Suit
• Lawyers To Supreme Court: Hear These Cases
• Case Study: In Re McNeil Consumer Healthcare
• NIDDK Can't Cancel Small Business Contract Offer: Judge
• Investor AB Spins Off Venture Capital Firm
• Merck To Pay $1.5M Penalty In EPA Pollution Case
• Insider Trading Suit Over Sanofi Deal Stays Alive
• Boston Sci Didn't Infringe Cordis Stent IP: Fed. Circ.
• Corporate Political Spending Post-Citizens United
• Asbestos Plaintiffs Pursue Pfizer For $10M In 2nd Circ.
• AstraZeneca GC Joins McDermott's Life Sciences Group
• Precision BioSciences Fires New Round In DNA IP Feud
• Another Beetle-Tainted Similac Suit Sliced Apart
• Blood Clot Risk May Rise With Some Contraceptives: FDA
• US Seeks Leukemia Drug Docs In Cephalon Marketing Probe
• Pfizer Targets Teva's Generic Viagra In Russia
• High Court To Mull If Winners Can Bill For Translation
• Hill-Rom Settles Medicare Fraud Case For $42M
• Cravath Reps AmerisourceBergen In $250M CVS Unit Buy
• Merck V. Garza: Now We're Really Confused
• Pain Med Testing Companies Battle Over False Ad Claims
• FDA Chemist Faces New Charges Before Possible Plea Deal
• Insurer Sues Kornegay Over Hepatitis B Claims Coverage
• Funds' Flonase Antitrust Suit Survives GSK Dismissal Bid
• AstraZeneca Settles Toprol Antitrust Action For $20M
• Boston Scientific Beats Investor Suit Over Bad Defibrillators
• Occlutech CEO Nabs Win In Patent Row With St. Jude Unit
• Guidant Settles FCA Claims For $9.25M
• Ky. Gets Purdue Oxycontin Case Sent To State Court
• RyMed, ICU Get New Trial In IV Valve Patent Fight
• Amgen Asks High Court To Take Up FCA Kickback Case
• Stan Lee's Co. Sued Over Sports Superhero Idea
• Isis Calls Out Santaris Over Drug Development Deals
• Judge Won't Rethink Ruling In Applied, Covidien IP Row
• J&J Scalpel Unit Can't Duck Tyco Patent Suit
• FTC Asks Omnicare For More Info On PharMerica Bid
• Patent Reform Law To Curb Inequitable Conduct Claims
• Sandoz Sues Watson, Amphastar Over Generic Lovenox
• Ex-Armor Co. Execs' $80M Insider Gains Off Limits: Judge
• Drugmaker Agrees To Reviews Over Fake Data Claims
• PharmAthene Wins Share Of SIGA Smallpox Drug Profits
• Medicis Settles Investors' Fraud Action For $18M
• Cephalon Challenges Sun's Anti-Epilepsy Generic
• 6th Circ. Affirms Toss Of Generic Drug Labeling Suits
• UPS, FedEx Settle Network Signatures IP Suits
• Greenberg Traurig Snags King & Spalding Patent Vet
• Bayer Unit Can't Stop Rival Acne Drug Statements: Judge
• Medtronic Must Produce InFuse Docs In Securities Suit
• FDA Yanks Ozone-Depleting Inhaler From Market
• J&J Washes Hands Of Baby Bath Products False Ad Suit
• Judge Bars Mylan's Generic Doryx For Now
• Roche, Mylan Settle Suit Over Generic Cancer Drug
• South Korea Fines Drug Cos. $9.6M Over Kickbacks
• Head Of France's Servier Probed Over Diabetes Drug
• White & Case Nabs Norton M&A Vet For Abu Dhabi Office
• Express Scripts Can't Shake Suit Over $29B Merger
• J&J Loses Bid For New Trial In $482M Stent Patent Case
• The 5 'PRs' Of Product Preservation
• Jury Hands Medtronic $101M In Spine Device IP Fight
• Sandoz Settles Texas Drug Inflation Claims For $66M
• Express Scripts, Medco Say Deal Will Boost Competition
• Excelsior Spread Lies About Rival's IV Cap, Suit Says
• How They Won It: Kaye Scholer Saves Pfizer's Viagra Patent
• Teva Must Pay Baxter's $144M Hepatitis Damages: Judge
• Cordis Loses Challenge Over USPTO Evidence Rules
• Dendreon Overstated Demand For Provenge: Investors
• Orix Unit Boosts Health PE Firm With $150M Infusion
• Boston Scientific Dodges Fraud Suit Over Firings
• Adidas Says Herbalife Breached Tri-Leaf Logo Deal
• FTC Investigates Valeant's Dermatology Buys
• Innovative Procedures V. Premarketing Approval
• Beckman Reaches $5.5M Settlement In Shareholder Suit
• FDA Chemist, US Close To Deal In Insider Trading Case
• Kramer Levin Opens Silicon Valley IP Office
• Genentech Says Prior Suit Bars HGS' Antitrust Claims
• Sun Pharma NJ Plant Passes FDA Review After Warning
• GSK OTC Products Spark Bidding War
• Court Joins 3 Google Investor Suits Over Illegal Drug Ads
• Sun Can't Sell Generic Eloxatin Until 2012: Judge
• Fresenius Sues InvaGen Over Generic PhosLo GelCaps
• Watson Exits Medicaid Drug Inflation MDL For $79M
• Ceragenix Whistleblower Takes $10M Suit To Colorado
• Metal Hip Implants Fail Faster Over Time: UK Report
• GSK's Zofran Could Lead To Abnormal Heart Rhythms: FDA
• Qualitest Recalls Mispackaged Birth Controll Pills
• Applied, Covidien Head To Trial Over Surgical Tool IP
• Cephalon Sues Sandoz Again Over Generic Fentora
• Ortho-McNeil Defends Foreign Patent Ruling In 7th Circ.
• Obama Signs Patent Reform Into Law
• Health Exam: Muni Health Care Bankruptcy Under Ch. 9
• Fenwal Didn't Infringe Blood Centrifuge Patent: Judge
• 2 Men Charged With Trading On Drug Co. Merger Tips
• Aurobindo Settles Medicis Patent Suit Over Solodyn
• Conflicting Post-Bilski Cases: Classen And CyberSource
• SC Johnson Sues Nutraceutical Over 'Bug Off' Mark
• Astellas Accused Of Delaying Generic Drug Approval
• J&J Units, Kremers Urban End Concerta Patent Suit
• J&J Unit To Shell Out $85M Over Bad Natrecor Labeling
• Case Study: Pernod V. Bacardi
• SEC Taps Fenwick Ace For Small Biz Investment Panel
• Takeda Hits Accord With Suit Over Actos ANDA
• Judge Greenlights Deal In Baby Sex Test Row
• Case Study: Interpharm V. Wells Fargo
• House Panel To Review Express Scripts' $29B Medco Buy
• FDA Warns Luitpold Over Drug Manufacturing Violations
• Mitsui Dodges Duke Hospital Contamination Suit Coverage
• Stock Promoter Gets 16 Months For Broker Bribery
• Nixon Peabody Expands Boston Team With Foley IP Attys
• Judge Clears HHS Financial Test For Equipment Suppliers
• Myriad — Fueling The Debate Over DNA Patents
• Sequenom Patent Agent Gets Probation For Insider Trading
• J&J Supplier's Bug Infestation Suit Survives Dismissal Bid
• PharMerica Sued Over Rebuffed $441M Omnicare Deal
• Caliper Investor Sues To Block $600M PerkinElmer Deal
• FTC Urges Pay-For-Delay Limits To Ease Deficit Woes
• Compound Animal Drugs Not Under FDA Authority: Court
• General Dynamics Settles DataTern Patent Suit
• US Pushes Drug Access Plan At Trans-Pacific Talks
• Ex-Howrey Chief Joins Winston & Strawn's Litigation Team
• Novelos Claims Securities Action Strikes Out
• Double Duty: Plaintiff's Doctor As Expert Witness
• GSK Sues Mylan, Impax Over Generic Prostate Drugs
• Flamel Seeks To Block Generic Coreg
• EU Trade Group Backs FDA's $300M Generics Fees Plan
• Dems Urge FTC To Dig Into Express Scripts-Medco Deal
• FDA Seeks Clearer Rules For Use Of Osteoporosis Meds
• Patent Reform Bill Clears Senate, Heads To Obama
• Genzyme Not Liable In Carticel Negligence Suit: 11th Circ.
• Hospital Bigwigs Off Hook In Medicare Fraud Suit
• Cadwalader M&A Heavyweight Jumps To Greenberg
• WilmerHale Reps PerkinElmer In $600M Caliper Buy
• AvMed Exits Class Suit Alleging Provigil Conspiracy
• Teva, Sandoz Infringed Allergan's Lumigan Patents: Judge
• Pfizer Didn't Breach Antitrust Laws: Indonesian Court
• Navy Holds On To Win Over $15M Drug Testing Contract
• The Skinny On Skinny Labels
• Express Scripts Sues Walgreen Over Disparagement
• Teva's Copaxone Trial Kicks Off Against Mylan, Sandoz
• Omnicare Takes $716M Bid For PharMerica Hostile
• Chinese Cos. Can't Shake Vitamin C Antitrust MDL
• Mylan, Cephalon Spar In Fed. Circ. Over Amrix MDL Ruling
• Case Study: SPX V. Master Cool
• Acorda Loses Patent Fight Over Apotex's Generic Zanaflex
• Shareholders Accuse Bovie Board Of Mismanagement
• Par, Others Targeted In Medicaid Fraud Suit
• $8M Settlement Reached In ArthroCare Shareholder Suit
• Abbott Can't Duck $3.5M Norvir Verdict For GSK: Judge
• Former Duane Reade CFO Skirts Prison Term
• FDA Questions Safety Of J&J, Bayer's Xarelto
• Ex-FDA Counsel Returns To Morgan Lewis
• Former Acting SG Katyal Heads To Hogan Lovells
• Amid Scandals, J&J CEO's Pay Was Too High: Suit
• The Myriad Appeal: DNA Patent-Eligibility Under § 101
• WebMD Faces Class Action Over Faulty Financials
• CardioNet Can't Escape IPO Class Action
• FDA Unveils New Fee Proposal For Drug Reviews
• FTC Eyes Evolving Pay-For-Delay Drug Deals
• Canadian Court Won't Let GSK Access Paxil Medical Docs
• Shook Hardy Nabs Fish & Richardson Health IP Pro
• Jury To Rule On Standing In UPenn Alzheimer's IP Row
• WebMD Shareholders Sue Board Over Rosy Forecasts